引用来源：

1.余艳琴，富诗岚，徐慧芳，韦梦娜，陈琦，胡尚英，赵方辉，乔友林. 中国大陆女性体检人群中人乳头瘤病毒型别感染率及九价疫苗中HPV各型别分布的系统评价[J]. 肿瘤预防与治疗, 2019, 32(2): 103-113.

2.Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, et al. Cancer survival in China, 2003–2005: a population-based study. Int J Cancer. 2015;136:1921–1930.

3.Drolet M, Bénard é, Pérez N, Brisson M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: Updated systematic review and meta-analysis. Lancet 2019; 394(10197):497-509.

4.Pitisuttithum P, Velicer C, Luxembourg A. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV[J]. Expert Rev Vaccines, 2015,14(11):1405-1419. DOI: 10.1586/14760584.2015.1089174.

5.Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet 2017; 390(10108):2143-2159.